Dialysis without heparin: a safety study
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether dialysis can be done safely without using heparin (a blood thinner) in people with end-stage kidney disease. If successful, it could reduce the need for blood-thinning medications and their associated risks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have been on dialysis for more than 3 months, with each session lasting at least 4 hours.
- You must not be taking any blood-thinning medications (other than what is given during dialysis).
- You must not have had a bad reaction to heparin in the past or have low platelets from heparin.
- You must not have any active bleeding or be at high risk for bleeding (e.g., recent surgery, stroke, or head injury within the last 7 days).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to do hemodialysis that might remove certain waste products (called protein-bound uremic toxins) more effectively than standard dialysis. It could help people on long-term dialysis feel better and have fewer complications.
This study compares two dialysis membranes while using a reduced “weaning” plan for the blood thinner heparin during hemodialysis. It aims to see which membrane works better and safely during routine chronic dialysis.
This trial compares two ways to prevent blood clots during a specific type of kidney dialysis called hemodiafiltration. If you have end-stage kidney disease and receive dialysis three times a week, this study may help doctors find the safest anticoagulation method for you.
This trial tests three study drugs (called monoclonal antibodies) in people with end-stage kidney disease who are on hemodialysis. The goal is to see if these drugs are safe and how they affect your body while you're on dialysis.
This trial tests adding a low dose of the blood thinner apixaban to the standard heparin lock solution used in tunneled hemodialysis catheters. The goal is to see if this combination keeps the catheter working better and longer than heparin alone.
This trial compares two blood thinners (heparin vs. hirudin) used during hemodialysis to prevent clots. It is for people who have recently started dialysis (within the last 6 months) and are between 18 and 70 years old.
Hear when a new End Stage Renal Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.